Boroń Dariusz, Agnieszka Seremak-Mrozikiewicz, Daniel Kotrych, Anna Bogacz, Adam Kamiński
Department of Histology and Embryology, Medical University of Silesia, Jordana 19, 41-808, Zabrze, Poland.
Division of Perinatology and Women's Diseases, Poznan University of Medical Sciences, 33 Polna Street, 60-535, Poznan, Poland.
Eur J Med Res. 2014 Dec 16;19(1):69. doi: 10.1186/s40001-014-0069-1.
Recognition of different genetic variants underlying osteoporosis would make it possible to introduce individual, symptomatic treatment as well as early prophylaxis of osteoporosis. The aim of the study was to evaluate the frequency of the rs2275913 (-197G > A) polymorphism of the IL-17 gene and assess the relation of this polymorphism with the clinical parameters of the osseous turnover and degree of the postmenopausal osteoporosis.
The study included 800 women of postmenopausal (505) and reproductive (295) ages throughout the Wielkopolska region in Poland. The postmenopausal group included women with osteoporosis and osteopenia, and those who were healthy. Women at reproductive age were healthy. The frequency of the tested gene polymorphism was evaluated in the group where bone mineral density (BMD) was marked and in the control group.
The results obtained showed that the T-score in the female population with osteopenia was remarkably lower in women showing the GG genotype of -197G > A polymorphism of IL-17 gene compared to patients with heterozygous GA genotype. It has been shown that the BMD value for L2-L4 YA in the evaluated female population with osteoporosis is significantly higher in women with the GA genotype of -197G > A polymorphism of IL-17 gene compared to women with the GG genotype (76.32% versus 59.93%, P <0.05). It has also been noted that the BMD value for L2 to L4 AM in patients with the GG genotype was lower than in women with the AA genotype (69.73% versus 80.88%, P <0.05).
It is suggested that the -197G > A polymorphism of the IL-17 gene may be considered as a genetic factor of postmenopausal osteoporosis. This polymorphism can influence the bone mineral density and T-score value in young women and postmenopausal women.
识别骨质疏松症潜在的不同基因变异将使引入个体化、对症治疗以及骨质疏松症的早期预防成为可能。本研究的目的是评估白细胞介素-17（IL-17）基因rs2275913（-197G＞A）多态性的频率，并评估该多态性与骨转换临床参数及绝经后骨质疏松症程度的关系。
该研究纳入了波兰大波兰地区800名绝经后（505名）和育龄期（295名）女性。绝经后组包括患有骨质疏松症和骨质减少症的女性以及健康女性。育龄期女性均为健康女性。在骨密度（BMD）有记录的组和对照组中评估所检测基因多态性的频率。
所得结果显示，与杂合子GA基因型患者相比，IL-17基因-197G＞A多态性GG基因型的女性骨质疏松症患者的T值显著更低。研究表明，在评估的骨质疏松症女性群体中，IL-17基因-197G＞A多态性GA基因型的女性L2-L4椎体面积骨密度（YA）值显著高于GG基因型女性（76.32%对59.93%，P＜0.05）。还注意到，GG基因型患者L2至L4腰椎正位面积骨密度（AM）值低于AA基因型女性（69.73%对80.88%，P＜0.05）。
提示IL-17基因-197G＞A多态性可能被视为绝经后骨质疏松症的一个遗传因素。这种多态性可影响年轻女性和绝经后女性的骨密度和T值。
